Long-acting factor VIII for severe hemophilia A
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and between 12 and 65 years old.
- You have severe hemophilia A (factor VIII level less than 1%).
- You have been treated with factor VIII products for at least 150 days in the past.
- You have no history of factor VIII inhibitors (antibodies that block treatment) and no current positive test.
- You do not have other bleeding disorders or serious health conditions that would raise risks.
- You agree to use effective contraception (if applicable) and not donate sperm during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
This trial tests a new form of factor VIII that lasts longer in the body, so you may need fewer infusions. It is for men with severe hemophilia A who have already used factor VIII products for at least 150 days.
This trial tests a new long-acting factor VIII treatment (FRSW107) for boys under 12 with severe hemophilia A. It aims to see if the drug is safe and effective at preventing or treating bleeding episodes.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This trial is testing a new injection called SR604 in people with congenital factor VII deficiency, a rare bleeding disorder. The study will check if the drug is safe and effective at preventing or treating bleeding episodes.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Hear when a new Severe Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.